5/16/2025
Last update
5/16/2025
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 5 Researches
7.6
USERS' SCORE
Good
Based on 6 Reviews
8.1
Supplement Facts
Serving Size: 1 Capsule
Amount Per Serving
%DV
Lactoferrin (as Apolactoferrin)
250 mg
†
Top Medical Research Studies
8
Lactoferrin peptide shows anticancer potential
We explored the potential of a synthetic peptide, derived from lactoferrin, to treat multiple myeloma, a type of cancer affecting plasma cells in the bone marrow. This peptide mimics the antibacterial properties of lactoferrin and appears to have anticancer effects as well.
In our experiments, the lactoferrin-derived chimera effectively inhibited the growth of multiple myeloma cell lines, including MM1S, MM1R, and RPMI8226. Notably, it induced both early and late stages of cell death in these cancer cells while sparing normal blood cells from damage.
Further analysis revealed that this peptide had a significant impact on the expression of genes tied to cell survival and apoptosis. We discovered that it triggers oxidative stress, leading to a generation of reactive oxygen species and mitochondrial dysfunction in cancer cells.
Importantly, while the peptide did not cause the typical caspase-dependent cell death we often observe in cancer treatments, it did promote a different form of apoptosis via the nuclear translocation of specific factors like apoptosis-inducing factor and endonuclease G.
Overall, this lactoferrin-derived peptide chimera shows promise in inducing a unique, caspase-independent form of cell death in multiple myeloma, suggesting it could be an effective new addition to cancer therapies.
In our experiments, the lactoferrin-derived chimera effectively inhibited the growth of multiple myeloma cell lines, including MM1S, MM1R, and RPMI8226. Notably, it induced both early and late stages of cell death in these cancer cells while sparing normal blood cells from damage.
Further analysis revealed that this peptide had a significant impact on the expression of genes tied to cell survival and apoptosis. We discovered that it triggers oxidative stress, leading to a generation of reactive oxygen species and mitochondrial dysfunction in cancer cells.
Importantly, while the peptide did not cause the typical caspase-dependent cell death we often observe in cancer treatments, it did promote a different form of apoptosis via the nuclear translocation of specific factors like apoptosis-inducing factor and endonuclease G.
Overall, this lactoferrin-derived peptide chimera shows promise in inducing a unique, caspase-independent form of cell death in multiple myeloma, suggesting it could be an effective new addition to cancer therapies.
Read More
8
We embarked on a journey to evaluate a novel treatment approach for glioblastoma, one of the most formidable types of brain cancer. Our research focused on creating a delivery system using lactoferrin in combination with vanadium complexes, known as LF-V4 nanoparticles.
This innovative nanoparticle system was designed to cross the blood-brain barrier effectively. It targeted glioblastoma cells, promoting a significant inhibition of tumor growth. We were excited to see that LF-V4 nanoparticles worked by inducing autophagic cell death in cancer cells through the generation of reactive oxygen species (ROS), which led to severe damage to the mitochondria.
Additionally, our findings revealed that these nanoparticles triggered lipid peroxidation. This reaction was fueled by an accumulation of ROS, a depletion of glutathione, and a decrease in specific proteins linked to cellular protection. Ultimately, this chain of events led to ferroptosis, a unique form of cancer cell death that could provide a new avenue for cancer treatments.
Overall, our exploration into lactoferrin's potential for combating glioblastoma demonstrates a promising direction in cancer research. It highlights the effectiveness of using targeted delivery systems to enhance treatment outcomes for patients facing one of the most challenging cancer types.
This innovative nanoparticle system was designed to cross the blood-brain barrier effectively. It targeted glioblastoma cells, promoting a significant inhibition of tumor growth. We were excited to see that LF-V4 nanoparticles worked by inducing autophagic cell death in cancer cells through the generation of reactive oxygen species (ROS), which led to severe damage to the mitochondria.
Additionally, our findings revealed that these nanoparticles triggered lipid peroxidation. This reaction was fueled by an accumulation of ROS, a depletion of glutathione, and a decrease in specific proteins linked to cellular protection. Ultimately, this chain of events led to ferroptosis, a unique form of cancer cell death that could provide a new avenue for cancer treatments.
Overall, our exploration into lactoferrin's potential for combating glioblastoma demonstrates a promising direction in cancer research. It highlights the effectiveness of using targeted delivery systems to enhance treatment outcomes for patients facing one of the most challenging cancer types.
Read More
9
We explored the potential of lactoferrin to improve the treatment of prostate cancer by enhancing the delivery of a specific drug, 2,2-dichloroacetophenone (DAP). DAP is a known inhibitor of Pyruvate Dehydrogenase Kinase 1 (PDK1), which plays a role in cancer cell metabolism and survival.
Our research showed that DAP can effectively inhibit the growth and spread of prostate cancer cells at lower concentrations compared to another agent, dichloroacetate. However, DAP's poor solubility posed a challenge for its use in clinical settings. By formulating DAP into nanoparticles conjugated with lactoferrin, we improved the drug's stability and targeted delivery to cancer cells that express high levels of lactoferrin receptors.
The lactoferrin-DAP nanoparticles not only demonstrated enhanced therapeutic effects in laboratory settings but also showed potent anti-tumor activity in mouse models. This formulation helped induce cell death and disrupted essential metabolic pathways in the cancer cells. Remarkably, these nanoparticles also proved effective against docetaxel-resistant cancer cells, suggesting a promising strategy to combat drug resistance.
Overall, targeting PDK1 with lactoferrin-conjugated DAP represents a novel approach to tackling prostate cancer by disrupting its metabolic processes.
Our research showed that DAP can effectively inhibit the growth and spread of prostate cancer cells at lower concentrations compared to another agent, dichloroacetate. However, DAP's poor solubility posed a challenge for its use in clinical settings. By formulating DAP into nanoparticles conjugated with lactoferrin, we improved the drug's stability and targeted delivery to cancer cells that express high levels of lactoferrin receptors.
The lactoferrin-DAP nanoparticles not only demonstrated enhanced therapeutic effects in laboratory settings but also showed potent anti-tumor activity in mouse models. This formulation helped induce cell death and disrupted essential metabolic pathways in the cancer cells. Remarkably, these nanoparticles also proved effective against docetaxel-resistant cancer cells, suggesting a promising strategy to combat drug resistance.
Overall, targeting PDK1 with lactoferrin-conjugated DAP represents a novel approach to tackling prostate cancer by disrupting its metabolic processes.
Read More
Most Useful Reviews
7.5
Helps canine cancer
10 people found this helpful
The product works well for me; I give it to my dog who has cancer, and it seems to be beneficial. The service has also been commendable.
Read More
7.5
Breast cancer growth
43 people found this helpful
I acquired this supplement for three main reasons: to protect against viruses and fungi, enhance iron absorption, and improve intestinal health. I learned that lactoferrin may inhibit the growth of breast cancer cells. However, I feel one course may not suffice to see significant results. Wishing everyone good health and a positive mindset!
Read More
7.5
Cancer cell control
6 people found this helpful
It is an essential nutritional supplement for cat owners. I knew it was useful for stomatitis, respiratory illnesses, and fungal skin diseases, but I was pleased to discover its effectiveness for anaemia and cancer as well. It reportedly plays a role in controlling the growth of cancer cells. The Life Extension and Jarrow products are affordable, which is why I always choose them.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 5 Researches
7.6
- All Researches
9
We explored the potential of lactoferrin to improve the treatment of prostate cancer by enhancing the delivery of a specific drug, 2,2-dichloroacetophenone (DAP). DAP is a known inhibitor of Pyruvate Dehydrogenase Kinase 1 (PDK1), which plays a role in cancer cell metabolism and survival.
Our research showed that DAP can effectively inhibit the growth and spread of prostate cancer cells at lower concentrations compared to another agent, dichloroacetate. However, DAP's poor solubility posed a challenge for its use in clinical settings. By formulating DAP into nanoparticles conjugated with lactoferrin, we improved the drug's stability and targeted delivery to cancer cells that express high levels of lactoferrin receptors.
The lactoferrin-DAP nanoparticles not only demonstrated enhanced therapeutic effects in laboratory settings but also showed potent anti-tumor activity in mouse models. This formulation helped induce cell death and disrupted essential metabolic pathways in the cancer cells. Remarkably, these nanoparticles also proved effective against docetaxel-resistant cancer cells, suggesting a promising strategy to combat drug resistance.
Overall, targeting PDK1 with lactoferrin-conjugated DAP represents a novel approach to tackling prostate cancer by disrupting its metabolic processes.
Our research showed that DAP can effectively inhibit the growth and spread of prostate cancer cells at lower concentrations compared to another agent, dichloroacetate. However, DAP's poor solubility posed a challenge for its use in clinical settings. By formulating DAP into nanoparticles conjugated with lactoferrin, we improved the drug's stability and targeted delivery to cancer cells that express high levels of lactoferrin receptors.
The lactoferrin-DAP nanoparticles not only demonstrated enhanced therapeutic effects in laboratory settings but also showed potent anti-tumor activity in mouse models. This formulation helped induce cell death and disrupted essential metabolic pathways in the cancer cells. Remarkably, these nanoparticles also proved effective against docetaxel-resistant cancer cells, suggesting a promising strategy to combat drug resistance.
Overall, targeting PDK1 with lactoferrin-conjugated DAP represents a novel approach to tackling prostate cancer by disrupting its metabolic processes.
Read More
9
We explored the promising combination of lactoferrin and radicicol for targeting prostate cancer cells. The study revealed that radicicol, a specific PDK1 inhibitor, effectively disrupted cancer cell growth, migration, and invasion, particularly in the LNCaP and PC-3 prostate cancer cell lines.
By encapsulating radicicol in lactoferrin nanoparticles, we observed significant improvements in its delivery, showing an 80% reduction in spheroid area—an indicator of cancer cell growth. This method takes advantage of overexpressed lactoferrin receptors found on many cancer cells, ensuring that the accumulated drug primarily affects the cancerous cells while sparing healthy ones.
Overall, the findings present a compelling case for lactoferrin-modified drug delivery systems in fighting prostate cancer, emphasizing both effectiveness and reduced side effects. This targeted approach may pave the way for more efficient treatment strategies in the future.
By encapsulating radicicol in lactoferrin nanoparticles, we observed significant improvements in its delivery, showing an 80% reduction in spheroid area—an indicator of cancer cell growth. This method takes advantage of overexpressed lactoferrin receptors found on many cancer cells, ensuring that the accumulated drug primarily affects the cancerous cells while sparing healthy ones.
Overall, the findings present a compelling case for lactoferrin-modified drug delivery systems in fighting prostate cancer, emphasizing both effectiveness and reduced side effects. This targeted approach may pave the way for more efficient treatment strategies in the future.
Read More
8
We embarked on a journey to evaluate a novel treatment approach for glioblastoma, one of the most formidable types of brain cancer. Our research focused on creating a delivery system using lactoferrin in combination with vanadium complexes, known as LF-V4 nanoparticles.
This innovative nanoparticle system was designed to cross the blood-brain barrier effectively. It targeted glioblastoma cells, promoting a significant inhibition of tumor growth. We were excited to see that LF-V4 nanoparticles worked by inducing autophagic cell death in cancer cells through the generation of reactive oxygen species (ROS), which led to severe damage to the mitochondria.
Additionally, our findings revealed that these nanoparticles triggered lipid peroxidation. This reaction was fueled by an accumulation of ROS, a depletion of glutathione, and a decrease in specific proteins linked to cellular protection. Ultimately, this chain of events led to ferroptosis, a unique form of cancer cell death that could provide a new avenue for cancer treatments.
Overall, our exploration into lactoferrin's potential for combating glioblastoma demonstrates a promising direction in cancer research. It highlights the effectiveness of using targeted delivery systems to enhance treatment outcomes for patients facing one of the most challenging cancer types.
This innovative nanoparticle system was designed to cross the blood-brain barrier effectively. It targeted glioblastoma cells, promoting a significant inhibition of tumor growth. We were excited to see that LF-V4 nanoparticles worked by inducing autophagic cell death in cancer cells through the generation of reactive oxygen species (ROS), which led to severe damage to the mitochondria.
Additionally, our findings revealed that these nanoparticles triggered lipid peroxidation. This reaction was fueled by an accumulation of ROS, a depletion of glutathione, and a decrease in specific proteins linked to cellular protection. Ultimately, this chain of events led to ferroptosis, a unique form of cancer cell death that could provide a new avenue for cancer treatments.
Overall, our exploration into lactoferrin's potential for combating glioblastoma demonstrates a promising direction in cancer research. It highlights the effectiveness of using targeted delivery systems to enhance treatment outcomes for patients facing one of the most challenging cancer types.
Read More
8
Lactoferrin peptide shows anticancer potential
We explored the potential of a synthetic peptide, derived from lactoferrin, to treat multiple myeloma, a type of cancer affecting plasma cells in the bone marrow. This peptide mimics the antibacterial properties of lactoferrin and appears to have anticancer effects as well.
In our experiments, the lactoferrin-derived chimera effectively inhibited the growth of multiple myeloma cell lines, including MM1S, MM1R, and RPMI8226. Notably, it induced both early and late stages of cell death in these cancer cells while sparing normal blood cells from damage.
Further analysis revealed that this peptide had a significant impact on the expression of genes tied to cell survival and apoptosis. We discovered that it triggers oxidative stress, leading to a generation of reactive oxygen species and mitochondrial dysfunction in cancer cells.
Importantly, while the peptide did not cause the typical caspase-dependent cell death we often observe in cancer treatments, it did promote a different form of apoptosis via the nuclear translocation of specific factors like apoptosis-inducing factor and endonuclease G.
Overall, this lactoferrin-derived peptide chimera shows promise in inducing a unique, caspase-independent form of cell death in multiple myeloma, suggesting it could be an effective new addition to cancer therapies.
In our experiments, the lactoferrin-derived chimera effectively inhibited the growth of multiple myeloma cell lines, including MM1S, MM1R, and RPMI8226. Notably, it induced both early and late stages of cell death in these cancer cells while sparing normal blood cells from damage.
Further analysis revealed that this peptide had a significant impact on the expression of genes tied to cell survival and apoptosis. We discovered that it triggers oxidative stress, leading to a generation of reactive oxygen species and mitochondrial dysfunction in cancer cells.
Importantly, while the peptide did not cause the typical caspase-dependent cell death we often observe in cancer treatments, it did promote a different form of apoptosis via the nuclear translocation of specific factors like apoptosis-inducing factor and endonuclease G.
Overall, this lactoferrin-derived peptide chimera shows promise in inducing a unique, caspase-independent form of cell death in multiple myeloma, suggesting it could be an effective new addition to cancer therapies.
Read More
4
Lactoferrin influences cancer therapy
We investigated how lactoferrin (LF), an iron-binding glycoprotein, affects cancer cells during radiation therapy, particularly when oxygen levels are low, known as hypoxic conditions. Our findings revealed that LF treatment can be toxic to a range of cells, both cancerous and non-cancerous. Interestingly, we noticed that hypoxic conditions made some cancer cells more sensitive to LF while reducing its effectiveness on non-cancer cells.
Furthermore, LF's impact on radiation treatment was complex. It increased the survival rate of non-cancer cells after radiation exposure, but it had the opposite effect on cancer cells, leading to reduced viability. What's critical is that these changes only happened when LF was administered shortly after radiation, not beforehand. When we examined the mechanisms at play, we found that LF influenced the production of reactive oxygen species (ROS) differently in each cell type—lowering ROS in non-cancer cells while increasing it in cancer cells.
Our deeper analysis showed that LF treatment modified the expression of genes associated with cell cycle, inflammation, and antioxidant pathways. Specifically, in non-cancer cells, LF decreased pro-apoptotic gene expression while in cancer cells, it affected NRF2-regulated genes. Knockdown experiments confirmed the roles of specific proteins in mediating these effects, suggesting that LF could serve different purposes in radiation therapy depending on the cell type.
Overall, this study highlights the potential of lactoferrin as a nuanced agent that could enhance or hinder radiation therapy based on the specific cellular context. Its effects on apoptosis and the NRF2 pathway showcase its possible use as either a protective agent or a sensitizer in treatment strategies.
Furthermore, LF's impact on radiation treatment was complex. It increased the survival rate of non-cancer cells after radiation exposure, but it had the opposite effect on cancer cells, leading to reduced viability. What's critical is that these changes only happened when LF was administered shortly after radiation, not beforehand. When we examined the mechanisms at play, we found that LF influenced the production of reactive oxygen species (ROS) differently in each cell type—lowering ROS in non-cancer cells while increasing it in cancer cells.
Our deeper analysis showed that LF treatment modified the expression of genes associated with cell cycle, inflammation, and antioxidant pathways. Specifically, in non-cancer cells, LF decreased pro-apoptotic gene expression while in cancer cells, it affected NRF2-regulated genes. Knockdown experiments confirmed the roles of specific proteins in mediating these effects, suggesting that LF could serve different purposes in radiation therapy depending on the cell type.
Overall, this study highlights the potential of lactoferrin as a nuanced agent that could enhance or hinder radiation therapy based on the specific cellular context. Its effects on apoptosis and the NRF2 pathway showcase its possible use as either a protective agent or a sensitizer in treatment strategies.
Read More
User Reviews
USERS' SCORE
Good
Based on 6 Reviews
8.1
- All Reviews
- Positive Reviews
- Negative Reviews
7.5
Helps canine cancer
10 people found this helpful
The product works well for me; I give it to my dog who has cancer, and it seems to be beneficial. The service has also been commendable.
Read More
7.5
Breast cancer growth
43 people found this helpful
I acquired this supplement for three main reasons: to protect against viruses and fungi, enhance iron absorption, and improve intestinal health. I learned that lactoferrin may inhibit the growth of breast cancer cells. However, I feel one course may not suffice to see significant results. Wishing everyone good health and a positive mindset!
Read More
7.5
Cancer cell control
6 people found this helpful
It is an essential nutritional supplement for cat owners. I knew it was useful for stomatitis, respiratory illnesses, and fungal skin diseases, but I was pleased to discover its effectiveness for anaemia and cancer as well. It reportedly plays a role in controlling the growth of cancer cells. The Life Extension and Jarrow products are affordable, which is why I always choose them.
Read More
7.5
Suppressing cancer growth
1 people found this helpful
Lactoferrin is a multifunctional glycoprotein crucial for iron metabolism. I have high ferritin levels linked to inflammation, and lactoferrin can modulate these levels effectively. It acts as a good immunomodulatory agent, has antimicrobial properties, and aids tissue regeneration. Recently, it has gained recognition as an anti-cancer agent, showing promise in suppressing cancer growth by enhancing the immune response. Lactoferrin is abundant in mammalian milk, which is vital for strengthening a baby's immunity.
Read More
7.5
Dog cancer support
12 people found this helpful
This supplement is helping my dog feel better during his struggle with cancer. He also takes N-tense and cell forte to support his health.
Read More
Frequently Asked Questions
7.5
Breast cancer growth
43 people found this helpful
I acquired this supplement for three main reasons: to protect against viruses and fungi, enhance iron absorption, and improve intestinal health. I learned that lactoferrin may inhibit the growth of breast cancer cells. However, I feel one course may not suffice to see significant results. Wishing everyone good health and a positive mindset!
8
Postoperative support
3 people found this helpful
I purchased this to help my mother during her breast cancer treatment as it boosts immunity. It has been beneficial for her postoperative recovery. The capsules are not overly large, making them suitable for elderly individuals as well.
7.5
Dog cancer support
12 people found this helpful
This supplement is helping my dog feel better during his struggle with cancer. He also takes N-tense and cell forte to support his health.
7.5
Cancer cell control
6 people found this helpful
It is an essential nutritional supplement for cat owners. I knew it was useful for stomatitis, respiratory illnesses, and fungal skin diseases, but I was pleased to discover its effectiveness for anaemia and cancer as well. It reportedly plays a role in controlling the growth of cancer cells. The Life Extension and Jarrow products are affordable, which is why I always choose them.
7.5
Suppressing cancer growth
1 people found this helpful
Lactoferrin is a multifunctional glycoprotein crucial for iron metabolism. I have high ferritin levels linked to inflammation, and lactoferrin can modulate these levels effectively. It acts as a good immunomodulatory agent, has antimicrobial properties, and aids tissue regeneration. Recently, it has gained recognition as an anti-cancer agent, showing promise in suppressing cancer growth by enhancing the immune response. Lactoferrin is abundant in mammalian milk, which is vital for strengthening a baby's immunity.
8
We embarked on a journey to evaluate a novel treatment approach for glioblastoma, one of the most formidable types of brain cancer. Our research focused on creating a delivery system using lactoferrin in combination with vanadium complexes, known as LF-V4 nanoparticles.
This innovative nanoparticle system was designed to cross the blood-brain barrier effectively. It targeted glioblastoma cells, promoting a significant inhibition of tumor growth. We were excited to see that LF-V4 nanoparticles worked by inducing autophagic cell death in cancer cells through the generation of reactive oxygen species (ROS), which led to severe damage to the mitochondria.
Additionally, our findings revealed that these nanoparticles triggered lipid peroxidation. This reaction was fueled by an accumulation of ROS, a depletion of glutathione, and a decrease in specific proteins linked to cellular protection. Ultimately, this chain of events led to ferroptosis, a unique form of cancer cell death that could provide a new avenue for cancer treatments.
Overall, our exploration into lactoferrin's potential for combating glioblastoma demonstrates a promising direction in cancer research. It highlights the effectiveness of using targeted delivery systems to enhance treatment outcomes for patients facing one of the most challenging cancer types.
This innovative nanoparticle system was designed to cross the blood-brain barrier effectively. It targeted glioblastoma cells, promoting a significant inhibition of tumor growth. We were excited to see that LF-V4 nanoparticles worked by inducing autophagic cell death in cancer cells through the generation of reactive oxygen species (ROS), which led to severe damage to the mitochondria.
Additionally, our findings revealed that these nanoparticles triggered lipid peroxidation. This reaction was fueled by an accumulation of ROS, a depletion of glutathione, and a decrease in specific proteins linked to cellular protection. Ultimately, this chain of events led to ferroptosis, a unique form of cancer cell death that could provide a new avenue for cancer treatments.
Overall, our exploration into lactoferrin's potential for combating glioblastoma demonstrates a promising direction in cancer research. It highlights the effectiveness of using targeted delivery systems to enhance treatment outcomes for patients facing one of the most challenging cancer types.
8
Lactoferrin peptide shows anticancer potential
We explored the potential of a synthetic peptide, derived from lactoferrin, to treat multiple myeloma, a type of cancer affecting plasma cells in the bone marrow. This peptide mimics the antibacterial properties of lactoferrin and appears to have anticancer effects as well.
In our experiments, the lactoferrin-derived chimera effectively inhibited the growth of multiple myeloma cell lines, including MM1S, MM1R, and RPMI8226. Notably, it induced both early and late stages of cell death in these cancer cells while sparing normal blood cells from damage.
Further analysis revealed that this peptide had a significant impact on the expression of genes tied to cell survival and apoptosis. We discovered that it triggers oxidative stress, leading to a generation of reactive oxygen species and mitochondrial dysfunction in cancer cells.
Importantly, while the peptide did not cause the typical caspase-dependent cell death we often observe in cancer treatments, it did promote a different form of apoptosis via the nuclear translocation of specific factors like apoptosis-inducing factor and endonuclease G.
Overall, this lactoferrin-derived peptide chimera shows promise in inducing a unique, caspase-independent form of cell death in multiple myeloma, suggesting it could be an effective new addition to cancer therapies.
In our experiments, the lactoferrin-derived chimera effectively inhibited the growth of multiple myeloma cell lines, including MM1S, MM1R, and RPMI8226. Notably, it induced both early and late stages of cell death in these cancer cells while sparing normal blood cells from damage.
Further analysis revealed that this peptide had a significant impact on the expression of genes tied to cell survival and apoptosis. We discovered that it triggers oxidative stress, leading to a generation of reactive oxygen species and mitochondrial dysfunction in cancer cells.
Importantly, while the peptide did not cause the typical caspase-dependent cell death we often observe in cancer treatments, it did promote a different form of apoptosis via the nuclear translocation of specific factors like apoptosis-inducing factor and endonuclease G.
Overall, this lactoferrin-derived peptide chimera shows promise in inducing a unique, caspase-independent form of cell death in multiple myeloma, suggesting it could be an effective new addition to cancer therapies.
9
We explored the potential of lactoferrin to improve the treatment of prostate cancer by enhancing the delivery of a specific drug, 2,2-dichloroacetophenone (DAP). DAP is a known inhibitor of Pyruvate Dehydrogenase Kinase 1 (PDK1), which plays a role in cancer cell metabolism and survival.
Our research showed that DAP can effectively inhibit the growth and spread of prostate cancer cells at lower concentrations compared to another agent, dichloroacetate. However, DAP's poor solubility posed a challenge for its use in clinical settings. By formulating DAP into nanoparticles conjugated with lactoferrin, we improved the drug's stability and targeted delivery to cancer cells that express high levels of lactoferrin receptors.
The lactoferrin-DAP nanoparticles not only demonstrated enhanced therapeutic effects in laboratory settings but also showed potent anti-tumor activity in mouse models. This formulation helped induce cell death and disrupted essential metabolic pathways in the cancer cells. Remarkably, these nanoparticles also proved effective against docetaxel-resistant cancer cells, suggesting a promising strategy to combat drug resistance.
Overall, targeting PDK1 with lactoferrin-conjugated DAP represents a novel approach to tackling prostate cancer by disrupting its metabolic processes.
Our research showed that DAP can effectively inhibit the growth and spread of prostate cancer cells at lower concentrations compared to another agent, dichloroacetate. However, DAP's poor solubility posed a challenge for its use in clinical settings. By formulating DAP into nanoparticles conjugated with lactoferrin, we improved the drug's stability and targeted delivery to cancer cells that express high levels of lactoferrin receptors.
The lactoferrin-DAP nanoparticles not only demonstrated enhanced therapeutic effects in laboratory settings but also showed potent anti-tumor activity in mouse models. This formulation helped induce cell death and disrupted essential metabolic pathways in the cancer cells. Remarkably, these nanoparticles also proved effective against docetaxel-resistant cancer cells, suggesting a promising strategy to combat drug resistance.
Overall, targeting PDK1 with lactoferrin-conjugated DAP represents a novel approach to tackling prostate cancer by disrupting its metabolic processes.
9
We explored the promising combination of lactoferrin and radicicol for targeting prostate cancer cells. The study revealed that radicicol, a specific PDK1 inhibitor, effectively disrupted cancer cell growth, migration, and invasion, particularly in the LNCaP and PC-3 prostate cancer cell lines.
By encapsulating radicicol in lactoferrin nanoparticles, we observed significant improvements in its delivery, showing an 80% reduction in spheroid area—an indicator of cancer cell growth. This method takes advantage of overexpressed lactoferrin receptors found on many cancer cells, ensuring that the accumulated drug primarily affects the cancerous cells while sparing healthy ones.
Overall, the findings present a compelling case for lactoferrin-modified drug delivery systems in fighting prostate cancer, emphasizing both effectiveness and reduced side effects. This targeted approach may pave the way for more efficient treatment strategies in the future.
By encapsulating radicicol in lactoferrin nanoparticles, we observed significant improvements in its delivery, showing an 80% reduction in spheroid area—an indicator of cancer cell growth. This method takes advantage of overexpressed lactoferrin receptors found on many cancer cells, ensuring that the accumulated drug primarily affects the cancerous cells while sparing healthy ones.
Overall, the findings present a compelling case for lactoferrin-modified drug delivery systems in fighting prostate cancer, emphasizing both effectiveness and reduced side effects. This targeted approach may pave the way for more efficient treatment strategies in the future.
References
- Gai S, Yan Q, Li S, Zhong X, Qin Y, et al. Lactoferrin Nanoparticle-Vanadium Complex: A Promising High-Efficiency Agent against Glioblastoma by Triggering Autophagy and Ferroptosis. J Med Chem. 2025;68:4650. 10.1021/acs.jmedchem.4c02696
- Jang YS, Dehkohneh SB, Lim J, Kim J, Ahn D, et al. Lactoferrin-Derived Peptide Chimera Induces Caspase-Independent Cell Death in Multiple Myeloma. Cells. 2025;14. 10.3390/cells14030217
- Subramaniam S, Jeet V, Gunter JH, Clements JA, Srinivasan S, et al. Lactoferrin-Encapsulated Dichloroacetophenone (DAP) nanoparticles enhance drug delivery and anti-tumor efficacy in prostate cancer. Cancer Lett. 2025. 10.1016/j.canlet.2025.217522
- Kooshan Z, Srinivasan S, Janjua TI, Popat A, Batra J. Lactoferrin conjugated radicicol nanoparticles enhanced drug delivery and cytotoxicity in prostate cancer cells. Eur J Pharmacol. 2025;991:177300. 10.1016/j.ejphar.2025.177300
- Murakami D, Fukazawa T, Kyo M, Miyauchi M, Ono S, et al. Lactoferrin Modulates Radiation Response Under Hypoxic Conditions, Possibly Through the Regulation of ROS Production in a Cell Type-Specific Manner. Antioxidants (Basel). 2024;14. 10.3390/antiox14010001
